Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527199 · ClinicalTrials.gov registry record
Prostate Cancer Patients With Biochemical Recurrence
A clinical trial of Patients With Prostate Cancer, sponsored by Medhat Osman.
- Completed
- Registry status
- 65
- Enrollment target
- 1
- Study location
NCT03527199 is a study of Patients With Prostate Cancer that has completed, run by Medhat Osman. The registered enrollment target is 65 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03527199, a study of Patients With Prostate Cancer, has completed, sponsored by Medhat Osman.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
Evaluation of detection rate of 18F-Fluciclovine compared to current standard of care imaging techniques within 30 days of the standard of care imaging study and a 6 month phone follow-up
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)
Study Locations (1)
Missouri
- John Cochran VA Medical Center St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2023-04-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03527199
The ClinicalTrials.gov registry entry for NCT03527199 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medhat Osman, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients With Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC) is the first listed.
NCT03527199 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03527199 about?
NCT03527199 is a clinical study titled "Prostate Cancer Patients With Biochemical Recurrence". Evaluation of detection rate of 18F-Fluciclovine compared to current standard of care imaging techniques within 30 days of the standard of care imaging study and a 6 month phone follow-up
What is the current status of trial NCT03527199?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2018-12-18. Estimated completion is 2023-04-10.
What conditions does trial NCT03527199 study?
This clinical trial studies the following conditions: Patients With Prostate Cancer.
What interventions are being tested in trial NCT03527199?
The interventions under investigation include: Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03527199?
This trial is sponsored by Medhat Osman, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03527199 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.